Ablynx Reaches Milestone In Tnf-Alpha Nanobody(R) Collaboration As Wyeth Pharmaceuticals (New Jersey) (WYE) Initiates Phase I  
12/10/2008 8:55:21 AM

Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, today announced that it has reached a milestone under the terms of its collaboration with Wyeth Pharmaceuticals, a division of Wyeth. A milestone payment of $3 million has been triggered by the initiation by Wyeth of a first Phase I study in healthy volunteers for a Nanobody® targeting tumour necrosis factor alpha (TNF-alpha).